Rubius Therapeutics surges 84% on encouraging results from early-stage testing of cancer treatment

NYSE traders
  • Rubius Therapeutics shares surged 84% during Monday’s trading session.
  • The biotech firm outlined encouraging data from testing of RTX-240, a potential cancer treatment.
  • Rubius said data collected provide initial proof-of-concept of its red blood cells generation system Red Platform.
  • See more stories on Insider’s business page.

Rubius Therapeutics shares more than doubled during Monday’s session after investors received the biotech firm’s outline of results from early-stage tests of a potential cancer drug.

The company said data from an ongoing clinical trial of patients with advanced solid tumors contributed to providing initial proof-of-concept for its platform to generate red blood cells.

Shares of Rubius jumped as much as 136% to $38.71 then trimmed closed the session up by 84%. Trading was heavy, with volume of nearly 38 million shares outrunning the average daily volume of about 1.5 million shares.

Among the data from an ongoing phase 1/2 trial of RTX-240, the company’s cellular therapy product candidate, there was a 54% reduction in target lesions in a patient with metastatic anal cancer.

Rubius said the data collected “provide clinical validation” of its Red Platform red blood cells generation system, said Pablo Cagnoni, chief executive at Rubius, in a statement.

With “encouraging” initial safety and preliminary efficacy data for RTX-240, he said the company plans to initiate a phase 2 expansion cohort in the first quarter of 2022 and a new phase 1 arm of the RTX-240 trial to evaluate it in combination with another therapy during the second half of 2021.

Read the original article on Business Insider

A 29-year-old woman who survived cancer as a child was just selected to fly to space aboard SpaceX’s rocket

SpaceX NASA
The SpaceX Falcon 9 rocket lifts off from Launch Complex 39-A at Kennedy Space Center. Joe Burbank/Orlando

  • 29-year-old childhood cancer survivor Hayley Arceneaux is set to board a SpaceX flight later this year.
  • Arceneaux will be joined by three others as part of the first-ever all-civilian crew to enter space.
  • Billionaire Jared Isaacman is chartering the flight and will select two more to join. 
  • Visit the Business section of Insider for more stories.

29-year-old Hayley Arceneaux, who survived cancer as a child, is the newest member of an all-civilian crew headed to space aboard a Falcon 9 rocket. 

Arceneaux had bone cancer as a child, but she had a list of life goals: beat cancer, learn Spanish, travel the globe, help other children with cancer, and someday, go to space, the Today Show reported. Arceneaux, now a physician assistant at St. Jude Research Hospital in Memphis, Tennessee, has checked off almost every goal. Now she’s set to achieve the last one after billionaire Jared Isaacman selected her to take one of four seats on a SpaceX flight he chartered for later this year. 

Isaacman founded payments company Shift4Payments. When he chartered the flight, he planned to fill the seats with himself, a St. Jude Children’s Research Hospital worker, and a Shift4Payments customer. The fourth seat is being raffled off to benefit childhood cancer research at St. Jude’s, for which Isaacman hopes to raise $200 million and donate $100 million out of his own pocket. The mission, called Inspiration4, will be the first to take off with an all-civilian crew and no professional astronauts. 

On Facebook, Arceneaux said, “I am so grateful for this incredible, once in a lifetime opportunity and honor, and I cannot WAIT to show the world what cancer survivors can do.”

SpaceX did not immediately respond to Insider’s request for comment. 

As a child, Arceneaux was treated for bone cancer at St. Jude’s, where she had metal rods replace parts of the bones in her left legs, The New York Times reported. That will make her the first person with a prosthetic body part to go to space, as well as the youngest American, the Times said. 

In a news release, Richard C. Shadyac Jr., head of the fundraising and awareness organization for St. Jude, said Arceneaux “will be an incredible ambassador through this mission and inspiration to children fighting cancer and survivors worldwide.” Others who will join Arceneaux and Isaacman will be announced in the coming weeks. 

Read the original article on Business Insider